| Predicate |
Object |
| contentType |
Comment|Journal Article |
| endingPage |
143 |
| issn |
1356-5524 |
| issueIdentifier |
5 |
| pageRange |
143-143 |
| publicationName |
Evidence-Based Medicine |
| startingPage |
143 |
| bibliographicCitation |
Ballew KA. Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis. Evid Based Med. 2006 Oct;11(5):143. doi: 10.1136/ebm.11.5.143. PMID: 17213145. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b8bb2acd7beda54c00478918e72066b |
| date |
2006-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://doi.org/10.1136/ebm.11.5.143
https://pubmed.ncbi.nlm.nih.gov/17213145 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1356-5524
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/32137 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60606
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9412
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10602 |